| 27,779 Euro | +0,361 +1,32 % | ||
| WKN: 850103 ISIN: US0028241000 Ticker-Symbol: ABL | Frankfurt | 19.06.13 | 09:02 Uhr |
Branche PharmaAktienmarkt S&P 100S&P 500 |
|
|
| Zeit | Aktuelle Nachrichten | |
|---|---|---|
| 18.06. | Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.65% Rise | |
Mehr lesen zu: Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.65% Rise | ||
| 17.06. | Abbott Loves Abbott Laboratories Stock | |
Mehr lesen zu: Abbott Loves Abbott Laboratories Stock | ||
| 17.06. | Abbott zahlt die 358. Quartalsdividende und kauft Aktien zurück | |
Mehr lesen zu: Abbott zahlt die 358. Quartalsdividende und kauft Aktien zurück | ||
| 15.06. | Abbott Declares Dividend and $3 Billion Buyback Plan | |
Mehr lesen zu: Abbott Declares Dividend and $3 Billion Buyback Plan | ||
| 14.06. | Abbott Progresses with Absorb in Japan | |
Mehr lesen zu: Abbott Progresses with Absorb in Japan |
| Zeit | Aktuelle Nachrichten | |
|---|---|---|
| 17.06. | Zealand Pharma A/S: Zealand informs of new Sanofi scientific presentations for Lyxumia® and of own presentation of a novel Zealand liquid glucagon analogue at the ADA's 73rd Scientific Sessions | |
| Copenhagen, 2013-06-17 07:30 CEST (GLOBE NEWSWIRE) --
- Scientific data on the post-prandial mechanism of action of Lyxumia® to be
presented
- Zealand to present own new data on a novel liquid glucagon... Mehr lesen zu: Zealand Pharma A/S: Zealand informs of new Sanofi scientific presentations for Lyxumia® and of own presentation of a novel Zealand liquid glucagon analogue at the ADA's 73rd Scientific Sessions | ||
| 12.06. | Zealand Pharma A/S: Zealand enters collaboration with D. E. Shaw Research with the objective of adding a new dimension to peptide drug design | |
| Copenhagen, 2013-06-12 14:00 CEST (GLOBE NEWSWIRE) --
- The collaboration will combine D. E. Shaw Research's state-of-the-art
computational capabilities with Zealand's broad-based discovery and development
competencies... Mehr lesen zu: Zealand Pharma A/S: Zealand enters collaboration with D. E. Shaw Research with the objective of adding a new dimension to peptide drug design | ||
| 31.05. | Zealand Pharma A/S: Zealand's presentation at the Jefferies 2013 Global Healthcare Conference to be webcast | |
| Copenhagen, 2013-05-31 12:08 CEST (GLOBE NEWSWIRE) --
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand"),a Danish
biotechnology company dedicated to the discovery and development of novel
peptide... Mehr lesen zu: Zealand Pharma A/S: Zealand's presentation at the Jefferies 2013 Global Healthcare Conference to be webcast | ||
| 28.05. | Zealand Pharma A/S: Zealand and Helsinn announce Helsinn's decision to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea | |
| - The decision follows promising findings from a Phase IIa Proof-of-Concept
study
- Helsinn is planning a Phase IIb study with elsiglutide, and study activities
are expected to start in H2 2013... Mehr lesen zu: Zealand Pharma A/S: Zealand and Helsinn announce Helsinn's decision to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea | ||
| 21.05. | Zealand Pharma A/S: Zealand to present at upcoming global healthcare investor conferences in the US | |
| Copenhagen, 2013-05-21 15:00 CEST (GLOBE NEWSWIRE) --
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand"), a Danish
biotechnology company dedicated to the discovery and development of novel
peptide... Mehr lesen zu: Zealand Pharma A/S: Zealand to present at upcoming global healthcare investor conferences in the US |
